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Metformin is considered the first line oral hypoglycaemic agent for the treatment of type 2 diabetes. We report three 
















All three cases were admitted to the intensive care unit to receive supportive care. Despite CVVHD, two patients died. 
 
Discussion  
Metformin is considered the first line oral hypoglycaemic agent. Confirmation of this diagnosis often proves difficult 
due to the scarcity of laboratory testing. Our case series highlights the issues of inappropriate prescription in specific 
patient populations.  
 
Introduction  
Metformin is considered the first line oral hypoglycaemic agent for the treatment of type 2 diabetes in the absence of 
contraindications1. Both the European Association for the study of Diabetes and the American Diabetes Association 
 
 
propose that metformin therapy be initiated, concurrent with lifestyle changes, once a diagnosis of diabetes has been 
made2. Metformin is contraindicated in patients with renal or hepatic insufficiency due to the increased risk of lactic 
acidosis3.Though metformin-associated lactic acidosis (MALA) is extremely rare (most estimates are ≤ 10 events per 
100,000 patient-years of exposure), cases continue to be reported3. MALA is well described in the literature but due 
to the low prevalence of testing for metformin levels it is usually a presumed diagnosis or one of exclusion. MALA is 
associated with mortality rates of 30 to 50%4. The criteria we use here to define metformin-associated lactic acidosis 
are those used by Kajbaf et al: arterial pH <7.35, blood lactate >5mmol/l and detectable plasma metformin 
concentration. Their study showed that although 869 cases were reported from 32 countries only 10.4% of cases met 
all three criteria5. Metformin has a therapeutic range of between 0.50.4mg/L6.  We present 3 cases of laboratory-
confirmed metformin-associated lactic acidosis in our intensive care unit. 
 
Case 1 
A 72-year-old female was brought in by ambulance with a recent history of increased alcohol intake, diarrhoea, 
abdominal pain and feeling generally unwell. Her past medical history included hypertension, peripheral vascular 
disease and non-insulin dependent diabetes. Medications on admission were, metformin (2g per day), amlodipine 
10mg, Ramipril 10mg, aspirin 75mg, simvastatin 40mg. Examination revealed agitation, bibasal scattered crepitations 
and mild abdominal distension. The abdomen was soft and non-tender. Vital signs and significant laboratory results 
shown in Table 1 and 2 respectively. Blood cultures taken on admission showed no growth after 5 days. The patient 
was transferred directly to the Intensive care unit (ICU). Central venous access and invasive blood pressure 
monitoring were established and inotropic support commenced. CT abdomen was performed after surgical 
consultation and the report concluded previous ischaemic colitis distal to the watershed area. The patient was brought 
to theatre for laparoscopy which showed distended small bowel with normal serosa and no free fluid. The patient 
remained intubated post-operatively and was commenced on continuous veno-venous haemodialysis filtration 
(CVVHDF). After initiation of CVVHDF the lactic acidaemia markedly improved to pH 7.2 and lactate 6.6 mmol/L. 
Metformin levels were elevated at 4.9 mg/L. The patient subsequently died after a prolonged ICU stay of 28 days 
following commencement of palliative measures 
 
Case 2 
A 56-year-old female was brought in by ambulance with a reduced level of consciousness. The patient had fallen the 
previous day and sustained a right eye and occipital laceration which were attended to by her GP. Her past medical 
history included non-insulin dependent diabetes, alcohol excess and depression. Her medications on admission were 
metformin 500mg BD, prothiaden 75mg nocte and esomeprazole 40mg OD. On initial examination the patient was co-
operative, chest auscultation revealed bibasal crepitations and abdominal examination was normal. Vitals signs and 
significant laboratory values shown in Table 1 and 2. Blood cultures taken on admission showed no growth after 5 
days. The patient deteriorated, with a significant drop in BP to 59/39 mmHg and she was transferred to the ICU. 
Inotropic/Vasopressor support, CVVHDF and non-invasive ventilation (NIV) were commenced. The next day the patient 
failed NIV and required intubation and mechanical ventilation. CT imaging of the thorax/abdomen/pelvis revealed no 
obvious source of sepsis. Metformin level decreased from 3.9mg/L to 1.15mg/L after CVVHDF. After a protracted ICU 
course (50 days) the patient was discharged to the ward and later home with no lasting sequela. 
 
Case 3 
72-year-old female self-presented to the emergency department with a one day history of diarrhoea and vomiting. 
Past medical history included non-insulin dependent diabetes, hypertension and hyperlipidaemia. Her medications on 
admission were metformin 850mg TDS, gliclazide 160mg mane/80mg nocte, simvastatin 20mg OD, amlodipine 10mg 
OD. On initial exam, the abdomen was soft but tender and bowel sounds were increased, GCS 15/15. Other vital signs 
and initial significant blood results are shown in Table 1 and 2 respectively. Blood cultures taken on admission showed 
no growth after 5 days. The patient deteriorated clinically and BP became unrecordable, her GCS fell to 4/15 and body 
temperature dropped to 31ºC. Hypoglycaemia was noted during this episode (blood glucose of 1.8mmol/L) which was 
treated with intramuscular glucagon. She was immediately transferred to the ICU where she had a cardiac arrest and 
was successfully resuscitated. Post arrest she remained intubated and ventilated and required increasing amounts of 
 
 
inotropic support. ABG revealed severe metabolic acidosis with pH 6.95 and lactate 27.6 mmol/l. Metformin levels 




 Case 1 Case 2 Case 3 
Respiratory Rate (breaths/minute) 28 26 16 
SpO2 % 100% 99% 96% 
Supplemental Oxygen FiO2 1.0 Room Air Room Air 
Heart Rate (bpm) 57 63 97 
Blood Pressure 69/39mmHg 104/56mmHg 143/87mmHg 






Metformin is a small molecule of 165kDA which is administered via the oral route. 150 minutes post administration 
maximum plasma concentrations are reached. The mean fractional oral bioavailability of metformin is 55 ± 16%7. The 
pharmacokinetics of metformin is assumed to be non-linear as its absorption is saturatable and incomplete. When 
used as intended, steady state plasma concentration is reached between 24 to 48 hours and is typically less then 1 
mcg/ml. Metformin has negligible plasma protein binding and the mean volume of distribution ranges between 63-
276L. Metabolites of metformin have not been identified and excretion of unchanged metformin occurs via the 
kidneys. Renal clearance of metformin is greater than 400 ml/min thus implying that metformin is eliminated by 
glomerular filtration plus tubular secretion. The apparent terminal elimination half-life is approximately 5 hours with 
normal renal function8. With impaired renal function clearance of metformin is decreased in proportion to that of 
creatinine therefore prolonging the elimination half-life and thus increasing plasma levels of metformin8. There has 
been no randomised control trial comparing the use of intermittent and continuous renal replacement therapy in 
MALA, however, numerous studies have shown continuous renal replacement therapy to be effective9. Acute alcohol 
intoxication and alcoholism are listed as contraindications to metformin therapy. Concomitant use of metformin and 
alcohol are not recommended as these are both independent risk factors for lactic acidosis10. Despite this, both Case 
1 and Case 2 had previous documented alcohol-related admissions and were continued on Metformin. With the 
widespread prescribing of metformin in primary care should more onus be placed on general practitioners to educate 
patients and obtain detailed social history prior to commencement of metformin? Although a relatively rare event we 
must have a high index of suspicion when patients on metformin present with non-specific signs of muscle cramps, 
abdominal pain, hypothermia, fatigue and a disproportionate rise in serum lactate as their clinical condition may 
deteriorate quickly. Confirming the diagnosis with laboratory investigation often proves difficult due to the scarce 
availability of testing and the turnaround time for results. In these three cases, serum samples for each patient were 
sent to a laboratory in France by Eurofins Biomnis. The methodology used by the laboratory was high performance 
liquid chromatography with a turnaround time of two weeks. 
Significant Laboratory Results 
 Case 1 Case 2 Case 3 
pH 6.7 7.2  
Lactate 22.6 14.8  
WBC 17.3 x109/L 4.3 x109/L 27.2 x109/L 
CRP 1.8 191.5 36.5 
Urea 11.2mmol/L 21.4mmol/L 16.4mmol/L 
Creatinine 134 µmol/L 387 µmol/L 142µmol/L 
Estimated GFR 36ml/min/1.73m2 11ml/min/1.73m2 34ml/min/1.73m2 
Metformin Levels 4.9mg/L 3.9mg/L 48.7mg/L 
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